A prime-boost concept using a T-cell epitope-driven DNA vaccine followed by a whole virus vaccine effectively protected pigs in the pandemic H1N1 pig challenge model. Issue 31 (18th July 2019)

• Record Type: Journal Article
• Authors: Hewitt, Joshua S.; Karuppannan, Anbu K.; Tan, Swan; Gauger, Phillip; Halbur, Patrick G.; Gerber, Priscilla F.; De Groot, Anne S.; Moise, Leonard; Opriessnig, Tanja
• Is Part Of: Vaccine. Volume 37:Issue 31(2019)
• Page Start: 4302
• Page End: 4309
• Publication Date: 2019-07-18
• Subjects: Influenza A virus -- Pigs -- DNA vaccine -- Prime boosting -- Intradermal vaccination -- T cell epitope -- Immunoinformatics; CMI cell mediated immunity -- EDV epitope driven vaccine -- HA hemagglutinin -- IAV influenza A virus -- NA neuraminidase -- PBMCs peripheral blood mononuclear cells -- PBS phosphate buffered saline -- pH1N1 pandemic H1N1 -- PSI pounds per square inch -- SLA swine leukocyte antigen; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.06.044
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Influenza A virus (IAV) vaccines in pigs generally provide homosubtypic protection but fail to prevent heterologous infections. In this pilot study, the efficacy of an intradermal pDNA vaccine composed of conserved SLA class I and class II T cell epitopes (EPITOPE) against a homosubtypic challenge was compared to an intramuscular commercial inactivated whole virus vaccine (INACT) and a heterologous prime boost approach using both vaccines. Thirty-nine IAV-free, 3-week-old pigs were randomly assigned to one of five groups including NEG-CONTROL (unvaccinated, sham-challenged), INACT-INACT-IAV (vaccinated with FluSure XP® at 4 and 7 weeks, pH1N1 challenged), EPITOPE-INACT-IAV (vaccinated with PigMatrix EDV at 4 and FluSure XP® at 7 weeks, pH1N1 challenged), EPITOPE-EPITOPE-IAV (vaccinated with PigMatrix EDV at 4 and 7 weeks, pH1N1 challenged), and a POS-CONTROL group (unvaccinated, pH1N1 challenged). The challenge was done at 9 weeks of age and pigs were necropsied at day post challenge (dpc) 5. At the time of challenge, all INACT-INACT-IAV pigs, and by dpc 5 all EPITOPE-INACT-IAV pigs were IAV seropositive. IFNγ secreting cells, recognizing vaccine epitope-specific peptides and pH1N1 challenge virus were highest in the EPITOPE-INACT-IAV pigs at challenge. Macroscopic lung lesion scores were reduced in all EPITOPE-INACT-IAV pigs while INACT-INACT-IAV pigs exhibited a bimodal distribution of low and high scores akin to naïve challenged animals. No IAV antigen in lung tissues was detected at necropsy in the EPITOPE-INACT-IAV group, which was similar to naïve unchallenged pigs and different from all other challenged groups. Results suggest that the heterologous prime boost approach using an epitope-driven DNA vaccine followed by an inactivated vaccine was effective against a homosubtypic challenge, and further exploration of this vaccine approach as a practical control measure against heterosubtypic IAV infections is warranted.